在肾移植中利用 B 细胞反应 - 现状和未来方向。
Harnessing the B Cell Response in Kidney Transplantation - Current State and Future Directions.
机构信息
Duke Transplant Center, Department of Surgery, Duke University School of Medicine, Durham, NC, United States.
出版信息
Front Immunol. 2022 Jun 9;13:903068. doi: 10.3389/fimmu.2022.903068. eCollection 2022.
Abstract
Despite dramatic improvement in kidney transplantation outcomes over the last decades due to advent of modern immunosuppressive agents, long-term outcomes remain poor. Antibody-mediated rejection (ABMR), a B cell driven process, accounts for the majority of chronic graft failures. There are currently no FDA-approved regimens for ABMR; however, several clinical trials are currently on-going. In this review, we present current mechanisms of B cell response in kidney transplantation, the clinical impact of sensitization and ABMR, the B cell response under current immunosuppressive regimens, and ongoing clinical trials for ABMR and desensitization treatment.
摘要
尽管由于现代免疫抑制剂的出现，肾移植的结果在过去几十年中得到了显著改善，但长期结果仍然不佳。抗体介导的排斥反应（ABMR）是一种 B 细胞驱动的过程，占大多数慢性移植物衰竭的原因。目前还没有 FDA 批准的 ABMR 治疗方案；然而，目前正在进行几项临床试验。在这篇综述中，我们介绍了肾移植中 B 细胞反应的当前机制、致敏和 ABMR 的临床影响、当前免疫抑制方案下的 B 细胞反应，以及正在进行的 ABMR 和脱敏治疗的临床试验。
相似文献
1
Harnessing the B Cell Response in Kidney Transplantation - Current State and Future Directions.在肾移植中利用 B 细胞反应 - 现状和未来方向。
Front Immunol. 2022 Jun 9;13:903068. doi: 10.3389/fimmu.2022.903068. eCollection 2022.
2
Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.硼替佐米用于肾移植受者难治性急性抗体介导排斥反应：一项单中心病例系列研究。
Nephrology (Carlton). 2016 Aug;21(8):700-4. doi: 10.1111/nep.12659.
3
What have we learned about how to prevent and treat antibody-mediated rejection in kidney transplantation?关于如何预防和治疗肾移植中抗体介导的排斥反应，我们学到了什么？
Am J Transplant. 2020 Jun;20 Suppl 4:12-22. doi: 10.1111/ajt.15859.
4
Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.高度人白细胞抗原致敏患者脱敏后移植的抗体介导排斥反应和移植物丢失的预测因素。
Transplantation. 2015 Jul;99(7):1423-30. doi: 10.1097/TP.0000000000000525.
5
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.克拉扎奇单抗用于治疗晚期抗体介导的排斥反应：一项随机对照试验的研究方案
Trials. 2019 Jan 11;20(1):37. doi: 10.1186/s13063-018-3158-6.
6
Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.由于持续/复发性与新发性供体特异性抗体导致的同种异体肾移植的抗体介导排斥反应的病理特征和移植物结局的差异。
Kidney Int. 2017 Mar;91(3):729-737. doi: 10.1016/j.kint.2016.10.040. Epub 2017 Jan 16.
7
Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).贝他西普在免疫风险因素轻微的肾移植受者中的应用：一项前瞻性研究（BELACOR）。
Am J Transplant. 2019 Mar;19(3):894-906. doi: 10.1111/ajt.15229. Epub 2019 Jan 25.
8
Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients.移植前共刺激阻断和蛋白酶体抑制剂脱敏可降低高致敏非人类灵长类动物肾移植受者的 DSA 并延迟抗体介导的排斥反应。
J Am Soc Nephrol. 2019 Dec;30(12):2399-2411. doi: 10.1681/ASN.2019030304. Epub 2019 Oct 28.
9
Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients.高敏儿科肾移植受者发生抗体介导排斥反应的危险因素。
Pediatr Transplant. 2017 Dec;21(8). doi: 10.1111/petr.13042. Epub 2017 Sep 19.
10
Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.监测循环供体反应性记忆 B 细胞对肾移植后抗体介导排斥反应的价值。
Am J Transplant. 2019 Feb;19(2):368-380. doi: 10.1111/ajt.15055. Epub 2018 Sep 17.
引用本文的文献
1
Comprehensive Phenotyping and Cytokine Production of Circulating B Cells Associate Resting Memory B Cells With Early Antibody-mediated Rejection in Kidney Transplant Recipients.循环B细胞的综合表型分析及细胞因子产生与肾移植受者静息记忆B细胞和早期抗体介导的排斥反应相关
Transplant Direct. 2025 Mar 20;11(4):e1775. doi: 10.1097/TXD.0000000000001775. eCollection 2025 Apr.
2
Characterization of immune phenotypes in peripheral blood of adult renal transplant recipients using mass cytometry (CyTOF).使用质谱流式细胞术（CyTOF）对成年肾移植受者外周血中的免疫表型进行表征。
Immunohorizons. 2025 Feb 18;9(4). doi: 10.1093/immhor/vlae013.
3
CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.CXCR5+CD8+T 细胞介导的对小鼠体液性同种异体免疫和 AMR 的抑制作用通过 mTOR 得到优化，通过钙调神经磷酸酶抑制作用受到损害。
Transplantation. 2024 Mar 1;108(3):679-692. doi: 10.1097/TP.0000000000004828. Epub 2023 Oct 24.
4
The impact of IdeS (imlifidase) on allo-specific, xeno-reactive, and protective antibodies in a sensitized rhesus macaque model.IdeS（免疫球蛋白蛋白酶）对致敏恒河猴模型中同种特异性、异种反应性和保护性抗体的影响。
Xenotransplantation. 2024 Jan-Feb;31(1):e12833. doi: 10.1111/xen.12833. Epub 2023 Oct 21.
5
Addition of interleukin-6 receptor blockade to carfilzomib-based desensitization in a highly sensitized nonhuman primate model.在高度致敏的非人类灵长类动物模型中，添加白细胞介素-6 受体阻断剂以增强基于卡非佐米的脱敏效果。
Am J Transplant. 2022 Dec;22 Suppl 4(Suppl 4):1-11. doi: 10.1111/ajt.17208.
6
A novel method for in vitro culture and expansion of nonhuman primate B cells.一种用于体外培养和扩增非人灵长类动物 B 细胞的新方法。
J Immunol Methods. 2022 Dec;511:113363. doi: 10.1016/j.jim.2022.113363. Epub 2022 Sep 26.
本文引用的文献
1
Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design.克拉扎珠单抗治疗肾移植受者慢性活动性抗体介导的排斥反应（AMR）：III 期 IMAGINE 研究的原理和设计。
Trials. 2022 Dec 22;23(1):1042. doi: 10.1186/s13063-022-06897-3.
2
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.单克隆 CD38 抗体 felzartamab 在晚期抗体介导的肾移植排斥反应中的安全性、耐受性和疗效：一项 2 期试验的研究方案。
Trials. 2022 Apr 8;23(1):270. doi: 10.1186/s13063-022-06198-9.
3
Shifting Clinical Trial Endpoints in Kidney Transplantation: The Rise of Composite Endpoints and Machine Learning to Refine Prognostication.在肾移植中转换临床试验终点：复合终点和机器学习在预后判断中的应用。
Transplantation. 2022 Aug 1;106(8):1558-1564. doi: 10.1097/TP.0000000000004107. Epub 2022 Mar 23.
4
Emerging biomarkers in kidney transplantation and challenge of clinical implementation.移植肾中的新兴生物标志物及其临床实施面临的挑战。
Curr Opin Organ Transplant. 2022 Feb 1;27(1):15-21. doi: 10.1097/MOT.0000000000000941.
5
The Multifaceted Roles of B Cells in the Thymus: From Immune Tolerance to Autoimmunity.B 细胞在胸腺中的多面角色：从免疫耐受到自身免疫。
Front Immunol. 2021 Nov 1;12:766698. doi: 10.3389/fimmu.2021.766698. eCollection 2021.
6
Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient.致敏肾移植受者的最佳免疫抑制策略
J Clin Med. 2021 Aug 18;10(16):3656. doi: 10.3390/jcm10163656.
7
Long-Term Survival after Kidney Transplantation.肾移植后的长期存活
N Engl J Med. 2021 Aug 19;385(8):729-743. doi: 10.1056/NEJMra2014530.
8
Donor-Specific Antibody Is Associated with Increased Expression of Rejection Transcripts in Renal Transplant Biopsies Classified as No Rejection.供体特异性抗体与被分类为无排斥的肾移植活检中排斥转录本的表达增加有关。
J Am Soc Nephrol. 2021 Nov;32(11):2743-2758. doi: 10.1681/ASN.2021040433. Epub 2021 Jul 12.
9
Disruption of Tfh:B Cell Interactions Prevents Antibody-Mediated Rejection in a Kidney Transplant Model in Rats: Impact of Calcineurin Inhibitor Dose.阻断滤泡辅助性 T 细胞与 B 细胞的相互作用可预防大鼠肾移植模型中的抗体介导排斥反应：钙调磷酸酶抑制剂剂量的影响。
Front Immunol. 2021 May 31;12:657894. doi: 10.3389/fimmu.2021.657894. eCollection 2021.
10
Therapies for Chronic Allograft Rejection.慢性移植物排斥反应的治疗方法。
Front Pharmacol. 2021 Apr 15;12:651222. doi: 10.3389/fphar.2021.651222. eCollection 2021.
Zotero 插件